167 related articles for article (PubMed ID: 2887076)
1. [Current therapy: immunopharmaceuticals].
Mahrle G
Z Hautkr; 1987 May; 62(10):753-6, 759-62, 765. PubMed ID: 2887076
[TBL] [Abstract][Full Text] [Related]
2. [Immunostimulants--therapeutic aspects].
Diezel W; Volk HD; Daniel V; Gruner S; Sönnichsen N
Arch Geschwulstforsch; 1989; 59(1):45-51. PubMed ID: 2493778
[TBL] [Abstract][Full Text] [Related]
3. Biologicals and biological response modifiers: fourth modality of cancer treatment.
Oldham RK
Cancer Treat Rep; 1984 Jan; 68(1):221-32. PubMed ID: 6198081
[TBL] [Abstract][Full Text] [Related]
4. Recent developments in immunomodulatory therapy.
Bardana EJ
J Allergy Clin Immunol; 1985 Apr; 75(4):423-40. PubMed ID: 2579994
[No Abstract] [Full Text] [Related]
5. [Immune modulators in the treatment of malignant melanoma].
Weiss J; Voigtländer V
Fortschr Med; 1989 Feb; 107(4):41-2, 45. PubMed ID: 2647601
[TBL] [Abstract][Full Text] [Related]
6. [Trends in the development of immunomodulators based physiopathological mechanisms of various types of hypersensitivities].
Abe T
Nihon Rinsho; 1983; 41(4):852-6. PubMed ID: 6887553
[No Abstract] [Full Text] [Related]
7. Biological response modifiers.
Oldham RK
J Natl Cancer Inst; 1983 May; 70(5):789-96. PubMed ID: 6188871
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulation as asthma therapy: where do we stand?
Barnes PJ
Eur Respir J Suppl; 1996 Aug; 22():154s-159s. PubMed ID: 8871062
[TBL] [Abstract][Full Text] [Related]
9. [Effect of splenin and zymosan on the immune system of patients with a soft tissue sarcoma].
Dziubko NIa; Tolstopiatov BA; Konovalenko VF; Chernenko OD; Redkousova SF
Vrach Delo; 1987 Jul; (7):81-3. PubMed ID: 2442892
[No Abstract] [Full Text] [Related]
10. [Drug therapy of vasculitis with immunosuppressive agents, immunomodulators and cyclosporin A].
Abe C
Nihon Rinsho; 1985 Oct; 43(10):2196-9. PubMed ID: 3912547
[No Abstract] [Full Text] [Related]
11. Immunosuppression and immunomodulation.
Goust JM; Stevenson H; Galbraith R; Virella G
Immunol Ser; 1993; 58():465-80. PubMed ID: 8424989
[No Abstract] [Full Text] [Related]
12. Managing HIV. Part 4: Primary therapy. 4.2 Immune-based therapy for HIV infection.
Benson EM; French MA; Schooley RT
Med J Aust; 1996 Mar; 164(5):297-300. PubMed ID: 8628166
[TBL] [Abstract][Full Text] [Related]
13. [Clinical value of immunotherapy for gynecological cancer by BRM (biological response modifier)].
Akiya K; Negishi Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):1025-9. PubMed ID: 2410519
[No Abstract] [Full Text] [Related]
14. Future perspectives for biological response modifiers: a viewpoint.
Mihich E
Semin Oncol; 1986 Jun; 13(2):234-54. PubMed ID: 2424090
[No Abstract] [Full Text] [Related]
15. [Concepts of stimulating immunotherapy].
Aiuti F; Montella F
Minerva Med; 1982 Apr; 73(15):895-8. PubMed ID: 6176915
[No Abstract] [Full Text] [Related]
16. Outlook for immune intervention in type I diabetes.
Grob PJ
Curr Probl Clin Biochem; 1983; 12():119-40. PubMed ID: 6360542
[No Abstract] [Full Text] [Related]
17. Therapeutic immunopharmacology.
Hadden JW
Curr Opin Immunol; 1989 Dec; 2(2):258-63. PubMed ID: 2483056
[No Abstract] [Full Text] [Related]
18. Immunotherapeutic agents: their role in cellular immunity and their therapeutic potential.
Chirigos MA; Talmadge JE
Springer Semin Immunopathol; 1985; 8(4):327-46. PubMed ID: 3911464
[No Abstract] [Full Text] [Related]
19. Immunotherapy of autoimmune diseases.
Bach JF
Recenti Prog Med; 1988; 79(7-8):343-50. PubMed ID: 3059421
[No Abstract] [Full Text] [Related]
20. Immunomodulators: current and future development and application.
Chirigos MA
Thymus; 1992; 19 Suppl 1():S7-20. PubMed ID: 1585422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
